Tempus AI (NASDAQ:TEM) Trading Up 5.2% – Here’s Why

Shares of Tempus AI, Inc. (NASDAQ:TEM) shot up 5.2% during mid-day trading on Friday . The company traded as high as $91.45 and last traded at $88.11. 13,619,652 shares were traded during mid-day trading, an increase of 2% from the average session volume of 13,370,095 shares. The stock had previously closed at $83.75.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on TEM. William Blair lowered Tempus AI from an “outperform” rating to a “market perform” rating in a report on Wednesday. Piper Sandler restated a “neutral” rating and set a $70.00 price target (up previously from $40.00) on shares of Tempus AI in a research note on Tuesday, November 12th. Bank of America lifted their price objective on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Wolfe Research started coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Loop Capital reduced their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research report on Tuesday, January 14th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $58.55.

Tempus AI Trading Up 6.8 %

The company has a 50-day simple moving average of $46.60 and a 200 day simple moving average of $50.32. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17.

Insider Buying and Selling

In other news, CEO Eric P. Lefkofsky sold 80,003 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $85.78, for a total value of $6,862,657.34. Following the sale, the chief executive officer now directly owns 5,049,460 shares in the company, valued at approximately $433,142,678.80. This represents a 1.56 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, major shareholder Bradley A. Keywell sold 265,000 shares of the stock in a transaction that occurred on Friday, January 17th. The stock was sold at an average price of $35.10, for a total value of $9,301,500.00. Following the completion of the transaction, the insider now directly owns 15,218,365 shares of the company’s stock, valued at approximately $534,164,611.50. The trade was a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,401,779 shares of company stock valued at $115,707,361.

Institutional Trading of Tempus AI

A number of large investors have recently bought and sold shares of the stock. Operose Advisors LLC acquired a new position in shares of Tempus AI in the 4th quarter worth approximately $25,000. First Horizon Advisors Inc. bought a new stake in shares of Tempus AI during the third quarter worth $30,000. Farther Finance Advisors LLC acquired a new stake in shares of Tempus AI in the fourth quarter valued at $34,000. Prestige Wealth Management Group LLC raised its holdings in shares of Tempus AI by 910.4% in the fourth quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after buying an additional 965 shares during the last quarter. Finally, NewEdge Advisors LLC acquired a new position in Tempus AI during the 4th quarter worth about $49,000. 24.22% of the stock is currently owned by institutional investors.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.